The details of infused cell doses, duration of hematologic recovery, and outcome of transplantation /kg). Tjan-Heijnen et al 3 demonstrated the impact of G-CSF priming on peripheral blood cell counts during chemotherapy. They showed a significant delay in neutrophil and platelet recovery in the group of small cell lung cancer patients undergoing conventional non-myeloablative chemotherapy with G-CSF primed chemotherapy. However, the implications for giving the G-CSF combined marrow ablative chemotherapy and PBSCT need to be elucidated.
Regarding the relatively high relapse rate of leukemia in our study, we found that the patients in continuous CR were transplanted with a lower number of CD34 + cells (2.2 and 5.7 × 10 6 /kg) than those patients who relapsed (8.8-20 .1 × 10 6 /kg). This might suggest the possibility of a higher chance of leukemic cell contamination with an increased dose of transplanted cells. Recently, Pecora 4 pointed out that multiple aphereses were needed in most patients to achieve stem cell doses greater than 5 × 10 6 /kg, and these procedures increased the malignant cell contamination of the apheresis product. In our study, all of the patients who did not suffer a relapse experienced apheresis procedures four times, and the patients with relapse experienced apheresis procedures five to six times. However, this hypothesis requires a parallel study on minimal residual disease to draw any conclusions about the necessity for purging. Another possible measure to decrease the potential for relapse after transplantation is to incorporate one or two cycles of consolidation following the induction therapy before mobilizing and harvesting the hematopoietic stem cells.
Because of the disappointing preliminary results, we are
Treatment of chronic GVHD
We thought that Gaziev et al 1 presented an excellent review of chronic GVHD. We believe that two important issues deserve further comment. In several sections regarding 'promising' drugs, the authors comment that the drug may be useful for treatment of chronic GVHD. We think that it is critical no longer recruiting patients for this protocol until data can be accumulated showing that G-CSF combined conditioning is beneficial in the PBSCT setting. to emphasize their comment in the abstract and conclusions that 'randomized clinical trials must be performed earlier in the course of cGVHD to establish the efficacy of these new drugs'. Although phase II trials suggest drug efficacy, only phase III trials can prove the impact of therapies. This was exactly the case for azathioprine, which was 'promising' in early studies, but which worsened outcome when added to prednisone therapy in a randomized phase III trial.
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Another very important point is the omission of hyd-roxychloroquine (HCQ) therapy of chronic GVHD. The omission itself may be understandable, since other drugs such as rapamycin and deoxyspergualin were also omitted, and it is a challenge to be comprehensive in a rapidly changing field. However, it is important to mention hydroxychloroquine because of the current status of clinical trials. We have published extensively on the immunomodulatory effects of HCQ on alloreactivity, immune responses, and preclinical GVHD models. 3-8 A phase II trial of HCQ has been presented twice.
9,10 The manuscript describing this trial is in press.
11
Most importantly, a very large phase III trial comparing standard therapy (prednisone/CsA) in combination with HCQ or placebo will open in July 2000. The trial will be funded by the NIH and conducted by the Children's Oncology Group. The trial also includes extensive laboratory evaluations to evaluate the pathogenesis of cGVHD. The trial represents the first randomized phase III multi-center trial of chronic GVHD, and will hopefully initiate a new mechanism for rapidly advancing our understanding of chronic GVHD and for determining the effectiveness of treatment. 
Response from Dr Gaziev
In our review, 1 we discussed the current situation of treatment for chronic GVHD. Consequently, we mainly presented the results of frequently used treatment approaches for this complication. Obviously we did not analyse all experimental drugs reported in the literature. Regarding hydroxychloroquine therapy for chronic GVHD we will consider it in our further studies.
Conventional drugs (prednisone, cyclosporine or azathioprine) have been used in randomised and non-randomised trials as conventional therapy for chronic GVHD. There are no convincing data published regarding the treatment of chronic GVHD with rapamycin or 15-deoxyspergualin. Regarding azathioprine, there must be caution when confirming 'worsened outcome when added to prednisone therapy'. The authors refer to the study of Sullivan et al. 3 This study was performed mainly in adult patients, while the efficacy and the safety of the addition of azathioprine to other immunosuppressive drugs as a part of combined treatment for chronic GVHD in paediatric patients have not yet been studied. Our results of using this drug as a part of combined immunosuppressive therapy (in the paediatric non-malignant BMT setting) resulted in high complete responses with acceptable morbidity and mortality (manuscript submitted to Bone Marrow Transplant).
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